...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: AHA 2018
3
Nov 09, 2018 08:43AM
1
Nov 09, 2018 12:43PM
4
Nov 10, 2018 05:02PM
4
bfw
Nov 10, 2018 06:45PM
4
Nov 10, 2018 10:13PM
5
Nov 10, 2018 11:04PM
3
Nov 11, 2018 05:03AM
1
Nov 11, 2018 08:05AM
2
Nov 11, 2018 08:53AM

Wow! Pulling out a 69 year old article! 

Both old and new reasons for why Amarin should have chosen a different placebo oil. Clear to me even w/o that old article that mineral oil was a horrible placebo choice. Despite this placebo issue, Vascepa clearly reduced 5- and 3- point MACE and other secondary endpoints in REDUCE-IT. Successful CVOT. Placebo issue complicates but doesn't compromise the REDUCE-IT trial.

BearDownAZ

5
Nov 11, 2018 10:41AM
3
Nov 11, 2018 03:21PM
5
Nov 11, 2018 09:56PM
4
Nov 11, 2018 11:46PM
4
Nov 12, 2018 07:32AM
2
Nov 12, 2018 08:07AM
4
Nov 12, 2018 09:22AM
1
Nov 12, 2018 11:29AM
3
Nov 12, 2018 11:49AM
2
Nov 12, 2018 08:48PM
Share
New Message
Please login to post a reply